0.51
0.51 (0%)
As of Feb 14, 2025
Bioaffinity Technologies, Inc. [BIAFW]
Source:
Company Overview
Bioaffinity Technologies, Inc. develop proprietary noninvasive diagnostics to detect early-stage lungcancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificialintelligence (“AI”).
| Country | United States |
| Headquarters | san antonio, texas |
| Phone Number | 210-698-5334 |
| Industry | |
| CEO | Maria Zannes |
| Website | www.bioaffinitytech.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $9.4 |
| Operating Profit | $-9 |
| Net Income | $-9 |
| Net Cash | $-1.7 |
Profit Ratios
| Gross Margin | $9.4 |
| Operating Margin | -95.6 |
| Profit as % of Revenues | -103.6% |
| Profit as % of Assets | -122.7% |
| Profit as % of Stockholder Equity | -347.4% |
Management Effectiveness
| Return on Equity | -347.4% |
| Return on Assets | -138.8% |
| Turnover Ratio | 127.1% |
| EBITA | $-8.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $6.5 |
| Total Liabilities | $3.9 |
| Operating Cash Flow | $-7.3 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $5.6 |
